UISH001

UISH001 is an investigational, sublingually administered small-molecule product candidate developed by Beech Tree Labs for symptomatic treatment of urinary incontinence. It was evaluated in a randomized, double-blind, placebo-controlled Phase 1/2a clinical study, NCT01340066; Beech Tree Labs reported completion of a 67-patient, multisite placebo-controlled Phase 2a evaluation in 2012. The active chemical identity, molecular structure, pharmacologic target, and mechanism of action have not been publicly disclosed in the identified primary and company-announcement sources. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01340066))

Other names

UISH-001UISH001UISH 001